# Alnylam Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alnylam-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.alnylam.com
- Total disclosed funding: $15M
- Latest round: Series B (Jul 20, 2002)
- Investors on record: 4

## About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative RNA interference (RNAi) therapeutics aimed at treating genetic diseases.Founded in 2002 and headquartered in Cambridge, US, Alnylam Pharmaceuticals specializes in RNAi therapeutics. The company completed its PIPE funding round, raising USD 150.00 mn from investors including the Blackstone Group. The firm has raised a total of USD 150.00 mn across six investment deals, with the most recent deal occurring on May 28, 2004. The company's leadership includes CEO John Maraganore and Yvonne Greenstreet, who have played instrumental roles in guiding its strategic direction.Alnylam Pharmaceuticals specializes in developing and commercializing innovative RNA interference (RNAi) therapeutics, focusing on conditions caused by gene dysfunction. Its key products include AMVUTTRA® (vutrisiran) for hereditary transthyretin-mediated amyloidosis (hATTR) and Qfitlia™ (fitusiran) for hemophilia. These therapeutics are designed to address the symptoms and underlying causes of genetic disorders, improving patient quality of life, and are marketed primarily in the United States and Europe.In the most recent fiscal year of 2023, Alnylam Pharmaceuticals reported revenue of USD 1,828.29 mn. The company also recorded an EBITDA of USD -185.14 mn for the same year. Alnylam generates revenue from the sale of its RNAi therapeutics, leveraging direct sales to healthcare providers and specialty pharmacies, supporting critical treatment needs in the healthcare ecosystem.Alnylam Pharmaceuticals is focused on expanding its product portfolio and market reach. The company plans to launch additional RNAi therapeutics targeting various genetic disorders in the near future. With the recent funding round, which raised USD 150.00 mn, Alnylam aims to enhance its research and development efforts, expand into new geographic markets, and further its mission of addressing unmet medical needs. The firm is particularly interested in entering markets in Europe and Asia by 2025, leveraging strategic partnerships to facilitate access to its innovative treatments.

## Funding rounds

- Series B, Jul 20, 2002, $15M — ARCH Venture Partners, Atlas Venture, Cardinal Partners, Polaris Partners
- Series A, Jan 1, 2001 — Cardinal Partners, Polaris Partners

## Investors

- Cardinal Partners (https://capitalatlas.ai/funds/cardinal-partners) — Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series B